CSL Ltd

CSL-AU:ASX
*Data is delayed | AUD
Last | 3:10 PM AET
267.50quote price arrow up+0.24 (+0.09%)
Volume
543,870
52 week range
242.67 - 342.75

...

Loading . . .

KEY STATS

  • Open269.24
  • Day High270.77
  • Day Low266.93
  • Prev Close267.26
  • 52 Week High342.75
  • 52 Week High Date02/20/20
  • 52 Week Low242.67
  • 52 Week Low Date03/23/20
  • Market Cap93,561.34M
  • Shares Out454.05M
  • 10 Day Average Volume746,002.27
  • Dividend1.47
  • Dividend Yield0.55%
  • Beta0.39
  • 1 Year % Change-10.86

RATIOS/PROFITABILITY

  • EPS (TTM)6.75
  • P/E (TTM)39.63
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest CSL Ltd News

There is no recent news for this security.

Latest CSL-AU News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma...
Brian McNamee
Non-Executive Chairman
Paul Perreault
Chief Executive Officer
Paul McKenzie Ph.D.
Chief Operating Officer
Joy Linton
Chief Financial Officer
Alan Wills
Executive Vice President
Address
45 Poplar Road,, Parkville
Melbourne, VIC
3052
Australia